SEOUL-SEMICONDUCTOR
From a research study 30% of dentists will suffer from visual reduction capabilities in the next 30 years. For FARO, the solutions are already here.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005033/en/
With the new dentist lamp Eva and the new ceiling panel Siderea equipped with SunLike LED technology, the historical and global market leader in the orthodontist equipment sector FARO wants to keep demonstrating their technological leadership and implement the latest technology available that can improve the healthcare of the users.
FARO has developed 2 new products with edge technology that will improve patients and doctors' lives, as new products include solar spectrum light that will help on concentration, relax and recovery activities as demonstrated by recent studies done by University of Basel and Harvard medical school.
The Eva lamp, completely developed, tested and manufactured in FARO headquarters in Ornago, near Milan, represents a technological revolution in the market. After many years of research the reflector is perfectly adapted to the new LED technology obtaining the perfect system combination that brings the best possible light and beam angle to the needed place.
The version Eva Sunlight uses the special SunLike LEDs from Seoul Semiconductor with a solar spectrum at any colour temperature of the light and produces the closest light to the real and natural Sunlight.
With an illumination of 50.000 lux the Eva luminaire can guide the professionals to see all the smallest details in their day to day operations and guarantee at the same time the maximum visual comfort for the patient and the dentist.
Talking about technical parameters the new luminaire is achieving the greatest quality of the light with a CRI of 97 and a TM30 of 100 that brings a perfect vision and colour reproduction of the oral cavities.
To get immediate feedback on the lighting level in use, you just have to take a look at the headlamp; it is also possible to manage all the functions from smartphones and tablets using the app FARO Tech that is available in all app stores.
Finally, Eva has an integrated camera (Eva Cam) which allows you to photograph and video record footage in FHD or even 4K to broadcast live or share images later on.
Siderea Sunlight is the natural complement of the Eva lamp. With the Theia Tech – the special lamp that talks with the intensive light – reducing the stress of the pre-operation for patients.
This combination of Siderea and Eva forms the FARO light system that has been developed to guarantee the ideal conditions for developing the dentists' work.
Siderea is the only dentist panel in the market with technology SunLike that mimics the effects of the natural light with a uniform, multidirectional and proportional light and it deletes all the shadows from traditional lamps. Reassuring the wellbeing and visual effects to operate in the perfect ambient.
“To improve people lives: this is our inspiration as entrepreneurs” explains Cristina Cesari, General Manager of FARO that today counts more than 700 customers, with products installed in more than 70 countries around the world.
“To reproduce the natural light is our main research driver and is a challenge of great fascination. Today we can bring the benefits of Seoul Semiconductor SunLike technology into the health medical area and improve all professional environments” added Cristina Cesari.
Oliver Schaefer, Executive Vice-president for Seoul Semiconductor Europe said “We are very honoured and proud to be part of the new FARO products with our latest LED technology SunLike that brings the Sun benefits to indoor spaces”.
About FARO
FARO is an historic Italian brand for lighting in the dental sector. FARO stands for high Italian quality, creativity and innovation. We provide products and “lighting systems” to improve the “light experience” because light is not only seen, but above all life and well-being. We are an enthusiastic company serving demanding and visionary customers. In FARO we provide cutting-edge technologies that are considered industry benchmarks, we work enthusiastically to go beyond the boundaries of research to enable the next generation of professional lighting.
About Seoul Semiconductor
Seoul Semiconductor develops and commercializes LEDs for automotive, general illumination, specialty lighting, and backlighting markets. As the second-largest LED manufacturer globally excluding the captive market, Seoul Semiconductor holds more than 14,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike, WICOP, NanoDriver and nPola as examples.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211207005033/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release
MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release
New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release
Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release
First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom